Aktie A3CM1D ANEBULO PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Anebulo Pharmaceuticals, Inc.

Aktien

A3CM1D

US0345691036

ANEB

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 02.07.2024 		% 5 Tage % 1. Jan.
2,49 USD -7,09 % Intraday Chart für Anebulo Pharmaceuticals, Inc. -11,07 % +2,89 %
15.05. Anebulo Pharmaceuticals, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 31. März 2024 CI
13.02. Anebulo Pharmaceuticals, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 31. Dezember 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
Anebulo Pharmaceuticals Announces New CEO
Anebulo Pharmaceuticals Appoints New CEO
Anebulo Pharmaceuticals Announces New CEO
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO
Anebulo Pharmaceuticals, Inc. Appoints Bimal Shah to Its Board of Directors
Anebulo Pharmaceuticals Appoints Daniel George as Part-Time Finance Chief
Anebulo Pharmaceuticals, Inc. Announces Chief Financial Officer Changes
Anebulo Pharmaceuticals, Inc. Appoints Daniel George as Principal Financial Officer and Principal Accounting Officer
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
Anebulo Pharmaceuticals : Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates - Form 8-K
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023
Kronos Bio Appoints Sandra Gardiner as Interim Chief Financial Officer
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CM1D Aktie
  4. Nachrichten Anebulo Pharmaceuticals, Inc.
  5. Andere Sprachen